<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Immunostimulants; Rituximab: malignant diseases; Alemtuzumab; Ofatumumab" /><meta name="IX" content="Immunostimulants; Rituximab: malignant diseases; Alemtuzumab; Ofatumumab" /><title>8.2.3 Anti-lymphocyte monoclonal antibodies: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="208986.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="208986.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=208986.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2075.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="4777.htm">8.2 Drugs affecting the immune response</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="27585.htm" title="Previous: TACROLIMUS">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="106036.htm" title="Next: ALEMTUZUMAB">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a301034.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Alemtuzumab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a310003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ofatumumab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a398003.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Antineoplastic Agents 10:00</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/18904-t.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Alemtuzumab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: A &gt; Interactions of Alemtuzumab</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/24508-j.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Ofatumumab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: O &gt; Interactions of Ofatumumab</p></div></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/17534-n.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Rituximab</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: R &gt; Interactions of Rituximab</p></div></li></ul><ul><li><h3>British National Formulary (9)</h3></li><li><a href="106036.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">ALEMTUZUMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Anti-lymphocyte monoclonal antibodies</p></div></li><li><a href="106037.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">MabCampath®</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Anti-lymphocyte monoclonal antibodies &gt; ALEMTUZUMAB</p></div></li><li><a href="206574.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">OFATUMUMAB</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Anti-lymphocyte monoclonal antibodies</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22immunostimulants%22%22rituximab%22%22alemtuzumab%22%22ofatumumab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (9)</a></li></ul><ul><li><h3>BNF for Children (5)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/4786.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">8.2.3 Rituximab and alemtuzumab</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/106036.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">ALEMTUZUMAB</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Rituximab and alemtuzumab</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/106037.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">MabCampath®</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 8 Malignant disease and immunosuppression &gt; 8.2 Drugs affecting the immune response &gt; 8.2.3 Rituximab and alemtuzumab &gt; ALEMTUZUMAB</p></div></li><li><a class="seeAll" href="http://www.medicinescomplete.com/mc/related.htm?q=%22immunostimulants%22%22rituximab%22%22alemtuzumab%22%22ofatumumab%22" onclick="pageTracker._trackEvent('Related-Topic','Related-See-All');">see all (5)</a></li></ul><ul><li><h3>Clarke's Analysis of Drugs and Poisons</h3></li><li><a href="http://www.medicinescomplete.com/mc/clarke/2010/CLK1471.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>Clarke's Analysis of Drugs and Poisons</strong> &gt; Monographs &gt; Alphabetically &gt; R</p></div></li></ul><ul><li><h3>Injectable Drugs Guide</h3></li><li><a href="http://www.medicinescomplete.com/mc/idg/2010/r06-mn0001.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>Injectable Drugs Guide</strong> &gt; Injectable Drugs Guide &gt; Monographs &gt; R</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/18904-t.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Alemtuzumab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/24508-j.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ofatumumab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/17534-n.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Antineoplastics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/00228.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Alemtuzumab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; A &gt; AL</p></div></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/10461.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Ofatumumab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; O &gt; OF</p></div></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/08239.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Rituximab</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; R &gt; RI</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions (2)</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E2E0E6E3E0R0D1722.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Alemtuzumab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; A</p></div></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E4E3E0R0D1722.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Rituximab</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; R</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_208986">8.2.3 Anti-lymphocyte monoclonal antibodies</h1><?highlighter on?><div id="pC" class="jN"><div><div id="_4786.1"><p><b><span>Rituximab</span></b> causes lysis of B lymphocytes. It is
licensed for the treatment of chemotherapy-resistant or relapsed stage
III–IV follicular non-Hodgkin’s lymphoma and, in combination with
other chemotherapy, for previously untreated stage III–IV follicular
lymphoma, and for previously untreated or relapsed chronic lymphocytic
leukaemia (see <a title="BNF:target-block: Rituximab NICE guidance (a)" href="208986.htm#_4786.3">NICE guidance</a> below).
Rituximab is also licensed for maintenance therapy in patients with
follicular non-Hodgkin’s lymphoma that has responded to induction
therapy (see <a title="BNF:target-block: Rituximab NICE guidance (c)" href="208986.htm#_200859">NICE guidance</a> below).
It is also licensed for use in combination with other chemotherapy
for the treatment of diffuse large B-cell non-Hodgkin’s lymphoma (see <a title="BNF:target-block: Rituximab NICE guidance (b)" href="208986.htm#_4786.4">NICE guidance</a> below). Full resuscitation facilities should be at hand and
as with other cytotoxics, treatment should be undertaken
under the close supervision of a specialist. See section
10.1.3 for the role of rituximab in rheumatoid arthritis.</p><p><span>Rituximab</span> should be used with caution in
patients receiving cardiotoxic chemotherapy or with a history of cardiovascular disease because exacerbation of angina, arrhythmia, and heart failure have been
reported. Transient hypotension occurs frequently during
infusion and antihypertensives may need to be withheld for 12 hours
before infusion. Progressive multifocal leucoencephalopathy
(which is usually fatal or causes severe disability) has been reported
in association with rituximab; patients should be monitored
for cognitive, neurological, or psychiatric signs and symptoms. If progressive multifocal leucoencephalopathy is suspected,
suspend treatment until it has been excluded.</p></div><div id="_208987"><p>Infusion-related side-effects (including cytokine release syndrome)
are reported commonly with anti-lymphocyte monoclonal antibodies and
occur predominantly during the first infusion; they include fever
and chills, nausea and vomiting, allergic reactions (such as rash,
pruritus, angioedema, bronchospasm and dyspnoea), flushing and tumour
pain. Patients should be given <span>paracetamol</span> and an antihistamine before each dose of anti-lymphocyte monoclonal
antibodies to reduce these effects. Premedication
with a corticosteroid should also be considered. The
infusion may have to be stopped temporarily and the infusion-related
effects treated—consult product literature for appropriate management. Evidence of pulmonary infiltration and features of tumour lysis syndrome
should be sought if infusion-related effects occur. </p><p>Fatalities following <b>severe</b> cytokine release
syndrome (characterised by severe dyspnoea) and associated with features
of tumour lysis syndrome have occurred after infusions of anti-lymphocyte
monoclonal antibodies. Patients with a high tumour burden as well
as those with pulmonary insufficiency or infiltration are at increased
risk and should be monitored <b>very closely</b> (and a
slower rate of infusion considered).</p></div><div id="_4786.3"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Rituximab for the treatment of follicular lymphoma
(September 2006)</h3><p>Rituximab, in combination with cyclophosphamide, vincristine,
and prednisolone is an option for the treatment of symptomatic stage
III and IV follicular lymphoma in previously untreated patients.</p></div></div><div id="_200859"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Rituximab for the treatment of relapsed or refractory
stage III or IV follicular non-Hodgkin’s lymphoma (February 2008)</h3><p>Rituximab, in combination with chemotherapy, is an option for
the induction of remission in patients with relapsed stage III or
IV follicular non-Hodgkin’s lymphoma.</p><p>Rituximab monotherapy as maintenance therapy is an option for
the treatment of patients with relapsed stage III or IV follicular
non-Hodgkin’s lymphoma in remission induced with chemotherapy (with
or without rituximab).</p><p>Rituximab monotherapy is an option for the treatment of patients
with relapsed or refractory stage III or IV follicular non-Hodgkin’s
lymphoma, when all alternative treatment options have been exhausted
(that is, if there is resistance to or intolerance of chemotherapy). </p></div></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Rituximab for the first-line maintenance treatment
of follicular non-Hodgkin’s lymphoma (June 2011)</h3><p>Rituximab maintenance therapy is recommended as an option for
the treatment of people with follicular non-Hodgkins’s lymphoma
that has responded to first-line induction therapy with rituximab
in combination with chemotherapy.</p></div><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Rituximab for the first-line treatment of chronic
lymphocytic leukaemia (July 2009)</h3><p>Rituximab, in combination with fludarabine and cyclophosphamide,
is recommended as an option for the first-line treatment of chronic
lymphocytic leukaemia.</p></div><div id="_4786.4"><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Rituximab for aggressive non-Hodgkin’s lymphoma (September
2003)</h3><p>Rituximab, in combination with cyclophosphamide, doxorubicin,
vincristine, and prednisolone, is recommended for first-line treatment
of CD20-positive diffuse large-B-cell lymphoma at clinical stage II,
III or IV.</p><p>The use of rituximab for localised (stage I) disease should
be limited to clinical trials.</p></div></div><div id="_1199893966517"><p><b>Alemtuzumab</b> causes lysis of B and T lymphocytes and is licensed for use in patients
with chronic lymphocytic leukaemia for whom fludarabine treatment
is not appropriate. <span id="_4786.2">In common with rituximab, it causes infusion-related side-effects
including cytokine release syndrome (see <a title="BNF:target-block: Anti-lymphocyte monoclonal antibodies and infusion-related side-effects" href="208986.htm#_208987">above</a>); premedication with paracetamol, an antihistamine, and a corticosteroid
is recommended.</span></p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (August 2008) that alemtuzumab is accepted for restricted
use within NHS Scotland for the treatment of B-cell chronic lymphocytic
leukaemia (B-CLL) when fludarabine combination chemotherapy is not
appropriate. Alemtuzumab is restricted to use in patients with previously
untreated B-CLL, with the cytogenetic abnormality 17p-deletion.</p></div><div id="_208988"><p><b>Ofatumumab</b> causes
lysis of B lymphocytes. It is licensed for treatment of chronic lymphocytic
leukaemia in patients refractory to fludarabine and alemtuzumab. Infusion-related
side-effects (including cytokine release syndrome—see <a title="BNF:target-block: Anti-lymphocyte monoclonal antibodies and infusion-related side-effects" href="208986.htm#_208987">above</a>) have been reported
with ofatumumab; premedication with paracetamol, an antihistamine,
and a corticosteroid is recommended.</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_106036"><a href="106036.htm" title="ALEMTUZUMAB">ALEMTUZUMAB</a></li><li id="_206574"><a href="206574.htm" title="OFATUMUMAB">OFATUMUMAB</a></li><li id="_70421"><a href="70421.htm" title="RITUXIMAB">RITUXIMAB</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="27585.htm">Previous: TACROLIMUS</a> | <a class="top" href="208986.htm#">Top</a> | <a accesskey="]" href="106036.htm">Next: ALEMTUZUMAB</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>